Consistent with ERα activities in the development, progression, and treatment of breast cancer, the endocrine therapy is used in clinical practice to interfere with cancer cell growth and survival through the inhibition of E2 synthesis (aromatase inhibitors) or the antagonism of ERα activation (e.g., fulvestrant, tamoxifen) [4,5]. Here, ESR1 is linked to breast cancer.